GUIDELINES


https://doi.org/10.5005/jp-journals-10071-23621
Indian Journal of Critical Care Medicine
Volume 24 | Issue Suppl 5 | Year 2020

Critical Care for COVID-19 Affected Patients: Updated Position Statement of the Indian Society of Critical Care Medicine

Yatin Mehta1, Dhruva Chaudhry2, OC Abraham3, Jose Chacko4, Jigeeshu Divatia5, Bharat Jagiasi6, Arindam Kar7, GC Khilnani8, Bhuvana Krishna9, Prashant Kumar10, RK Mani11, BK Rao12, Pawan K Singh13, Sanjeev Singh14, Pavan Tiwary15, Chand Wattal16, Deepak Govil17, Subhal Dixit18, Srinivas Samavedam19

1Department of Critical Care and Anesthesiology, Medanta: The Medicity, Gurugram, Haryana, India
2,13Department of Pulmonary and Critical Care, Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India
3Infectious Disease Medicine, Christian Medical College, Vellore, Tamil Nadu, India
4Critical Care Medicine, Narayana Hrudyala, Bengaluru, Karnataka, India
5Critical Care and Anesthesia, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
6Department of Critical Care, Reliance Hospital, Navi Mumbai, Maharashtra, India
7CK Birla Hospitals, Gurugram, Haryana, India; CMRI Institute of Critical Care, Kolkata, West Bengal, India; Indian Society of Critical Care Medicine; European Society of Intensive Care Medicine
8Department of Pulmonary, Critical Care and Sleep Medicine, PSRI Hospital, New Delhi, India
9Department of Critical Care Medicine, St. John’s Hospital, Bengaluru, Karnataka, India
10Department of Anaesthesiology, Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India
11Critical Care and Pulmonology, Batra Hospital and Medical Research Centre, New Delhi, India
12Department of Critical Care and Emergency Medicine, Sir Ganga Ram Hospital, New Delhi, India
14Amrita Institute of Medical Sciences, Ernakulam, Kerala, India; Amrita Hospitals, Faridabad, Haryana, India
15All India Institute of Medical Sciences, New Delhi, India
16Clinical Microbiology and Immunology, Sir Ganga Ram Hospital, New Delhi, India
17Institute of Critical Care and Anesthesiology, Medanta: The Medicity, Gurugram, Haryana, India
18Department of Critical Care Medicine, Sanjeevan and MJM Hospital, Pune, Maharashtra, India
19Department of Critical Care, Virinchi Hospital, Hyderabad, Telangana, India

Corresponding Author: Dhruva Chaudhry, Department of Pulmonary and Critical Care, Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India, Phone: +91 9991101616, e-mail: dhruvachaudhary@yahoo.co.in

How to cite this article Mehta Y, Chaudhry D, Abraham OC, Chacko J, Divatia J, Jagiasi B, et al. Critical Care for COVID-19 Affected Patients: Position Statement of the Indian Society of Critical Care Medicine. Indian J Crit Care Med 2020;24(Suppl 5):S225–S230.

Source of support: Nil

Conflict of interest: None

ABSTRACT

The management of coronavirus disease-2019 (COVID-19) is witnessing a change as we learn more about the pathophysiology and the severity of the disease. Several randomized controlled trials (RCTs) and meta-analysis have been published over the last few months. Several interventions and therapies which showed promise in the initial days of the pandemic have subsequently failed to show benefit in well-designed trials. Understanding of the methods of oxygen delivery and ventilation have also evolved over the past few months. The Indian Society of Critical Care Medicine (ISCCM) has reviewed the evidence that has emerged since the publication of its position statement in May and has put together an addendum of updated evidence.

Keywords: Convalescent plasma, COVID-19, SARS-CoV-2.

OXYGENATION AND VENTILATION

Hypoxemia is the most common indication for hospitalization of coronavirus disease-2019 (COVID-19) patients. Conventional oxygen therapy may not be sufficient among moderately and severely ill patients. Options for such patients include high-flow nasal cannula (HFNC), noninvasive ventilation (NIV), invasive ventilation, and extracorporeal membrane oxygenation (ECMO). High-flow nasal cannula seems to result in more ventilator-free days compared to NIV among non-COVID-19 patients.1

Prone positioning has been successfully used for managing hypoxemic respiratory failure. Awake proning is a concept that has emerged during the pandemic and has widely been used.2,3 Small case series have shown reduced intubation rates with the awake proning strategy.

Indian Society of Critical Care Medicine (ISCCM) position—revised take home points:

EXTRACORPOREAL MEMBRANE OXYGENATION

ECMO has been suggested by the WHO in its guidance document issued in March. The current evidence for ECMO as a treatment modality for severe COVID-19 is equivocal.3 Advanced age, comorbidities, and lymphopenia seem to be determinants of adverse outcome with ECMO. Results seem to be better with the use of ECMO, in the context of a cytokine storm.2 The Extracorporeal Life Support Organization (ELSO) has released a consensus document on the use of ECMO for COVID-19.4 Indications and contraindications for the use of ECMO have been listed in this guideline. The guideline recommends ECMO to be offered in experienced centers rather than compromise existing infrastructure in non-ECMO centers.

Indian Society of Critical Care Medicine Position—revised take home points:

CORTICOSTEROIDS

The potent anti-inflammatory effects of corticosteroids make them an attractive option for blunting the inflammatory response associated with COVID-19. The RECOVERY trial demonstrated a survival benefit among hypoxemic patients treated with dexamethasone (6 mg/day for 10 days or till hospital discharge). The CODEX RCT5 was a multicenter open-label randomized controlled trial (RCT), evaluating the benefit of using dexamethasone in moderate-to-severe COVID-19-related acute respiratory distress syndrome (ARDS). The primary endpoint was ventilator-free days at 28 days, which was found to be significantly better in the dexamethasone group. The REMAP-CAP COVID-19 study6 and the CAPE-COVID trial7 evaluated the effect of hydrocortisone among patients requiring cardiovascular and respiratory organ support. Both the studies failed to show any superiority for hydrocortisone over standard therapy. The MET COVID trial8 evaluated the effect of methylprednisolone among patients hospitalized for COVID-19. The intervention was used for patients requiring oxygen supplementation. The primary outcome was 28-day mortality which was not influenced by the intervention. A meta-analysis published in JAMA, from the WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, found that in critically ill COVID-19 patients, administration of corticosteroids was associated with reduced mortality.9 The evidence was strongest for the use of dexamethasone (0.64, 95% CI, 0.50–0.82; p %3C; 0.001), since it involved largest number of patients (3 trials, 1,282 patients, and 527 deaths), as compared to the hydrocortisone (0.69, 95% CI, 0.43–1.12; p = 0.13, 3 trials, 374 patients) or methylprednisolone (0.91, 95% CI, 0.29–2.87; p = 0.87 and 1 trial, 47 patients).

Indian Society of Critical Care Medicine Position—updated take home points:

Effective doses of steroids have to be understood and followed during prescription.

DrugDose (mg)
Hydrocortisone20
Cortisone acetate25
Prednisone  5
Prednisolone  5
Deflazacort  6
Methylprednisolone  4
Dexamethasone  0.75
Betamethasone  0.75
Triamcinolone  4
Beclometasone  0.75

PHARMACOLOGICAL TREATMENT

Chemoprophylaxis

At present, no agent has been proven to be effective for pre-exposure prophylaxis against COVID-19. Several agents including hydroxychloroquine (HCQ), ivermectin, tenofovir plus emtricitabine, vitamin C, vitamin D, and zinc have been studied or are under investigation with no demonstrable benefit. Similarly, no drug has been shown to be effective for post-exposure prophylaxis either. Boulware et al. could not demonstrate a reduction in symptomatic disease with the use of hydroxychloroquine sulfate (HCQS) as post-exposure prophylaxis.10

Indian Society of Critical Care Medicine Position—Revised take home points

  • No single agent or a combination of agents can be recommended for either pre- or post-exposure prophylaxis against COVID-19 (SR, HQE).

THERAPY

Several RCTs evaluating therapy for COVID-19 have been initiated and some have been published.

Azithromycin was one of the first drugs to be used for the treatment of COVID-19. Furtado et al.11 evaluated the effect of adding azithromycin to standard therapy that included HCQS as part of the COALITION II study. This was an open-label RCT across 57 Brazilian centers that enrolled 447 patients over a 2-month period. The authors could not demonstrate a treatment benefit with the addition of azithromycin. However, the incidence of adverse events was not increased.

Chloroquine and HCQS have been evaluated in multiple studies (including RCTs) for both safety and efficacy. Rosenberg et al.12 in a large RCT among hospitalized patients could not show a decrease in 28-day mortality with the use of HCQS. Median hospital stay was, in fact, longer in the HCQS group. In addition, large retrospective observational studies do not show benefit with HCQS. The ongoing RECOVERY trial11 ended the HCQS arm on June 5, after an independent data monitoring committee could not find a beneficial effect with HCQS.

Ivermectin, of late, has been proposed as a therapeutic option for COVID-19 in view of its ability to inhibit the replication of SARS-CoV-2 virus in cell cultures. The only RCT evaluating ivermectin compared to a combination of ivermectin (200 μg/kg) with doxycycline to a combination of HCQS and azithromycin.13 In this small study of 181 patients, a single dose of ivermectin combined with doxycycline did not fare better than a combination of HCQS and azithromycin.

Lopinavir/ritonavir combination was known to be effective against SARS-CoV. Several RCTs14–16 evaluating the combination have failed to show a clinical benefit among moderately to severely ill COVID-19 patients.

Remdesivir inhibits viral replication through premature termination of RNA transcription. In a multinational RCT of remdesivir vs placebo for severe COVID-19,17 the authors demonstrated a significant reduction in the time to recovery. The benefit was clearest in the group requiring oxygen. However, the benefit was not obvious in those requiring HFNC/NIV. Recovery was also not better among those who were on invasive ventilation or ECMO. In a study which excluded patients needing invasive ventilation or ECMO, or having MOF, clinical improvement was no different among those who received remdesivir.18 A 10-day course of remdesivir was not found to be superior to a 5-day course in an RCT.19 A network meta-analysis of use of remdesivir in moderately to severely ill patients (2,049 patients) confirmed these findings.9 A large trial in moderately ill COVID-19 596 patients, compared the efficacy of 5 or 10 days of remdesivir treatment compared with standard care on clinical status. There was no difference in outcomes after a 5- vs 10-day course of remdesivir and though the patients who received a 5-day course of remdesivir had statistically better outcomes at 11 days, the clinical significance of this finding was uncertain.9

Indian Society of Critical Care Medicine Position—Revised take home points:

(i) No drug can be recommended for chemoprophylaxis.

IMMUNOMODULATORY THERAPIES

IL-6 Inhibitors

Increased cytokine release as evidenced by increased levels of IL-6, c reactive protein (CRP), D-dimer, and ferritin may be responsible for the severity of SARS-CoV-2 infection. Two classes of IL-6 inhibitors are available, which could have theoretical benefit in the setting of raised IL-6 levels. These are the anti-IL6 receptor monoclonal antibodies (sarilumab, tocilizumab) and anti-IL6 monoclonal antibodies (siltuximab). The most widely used molecule in India is tocilizumab. The industry sponsored COVACTA phase 3 trial20 evaluating the effect of tocilizumab on clinical improvement did not show a significant benefit in terms of need for invasive ventilation and intensive care. Observational21 and retrospective22 studies did show a benefit.

Indian Society of Critical Care Medicine Position—Updated take home point:

  • There is no strong evidence to recommend the use of tocilizumab as standard treatment for COVID-19 (WR, LQE).

Interferons (Alfa and Beta)

Interferons are cytokines with antiviral properties. Previous studies during the MERS-CoV and SARS outbreaks have failed to show benefit. A double-blind placebo-controlled trial23 evaluating interferon-beta 1a demonstrated a quicker recovery to ambulation among a cohort of 50 patients. Another similar small study24 using a subcutaneous formulation failed to show a clinical benefit.

Indian Society of Critical Care Medicine Position—New

  • Interferon therapy cannot be recommended as a standard therapy based on current evidence (SR, LQE).

Antithrombotic Therapy

COVID-19 is associated with inflammation and a prothrombotic state. This state is characterized by increased D-dimer values. Patients hospitalized in intensive care units seem to have a higher incidence of venous thromboembolism (VTE). The incidence ranges from 16 to 69%.25–27 Data regarding benefit from monitoring coagulation markers and treating with anticoagulants are scanty. The WHO has provided some answers in its interim guidance.28,29 The Society of Thrombosis and Haemostasis Research has also issued guidelines for the initiation of treatment, drug dosing, and duration of pharmacological VTE prophylaxis in COVID-19 patients.

Indian Society of Critical Care Medicine Position—Updated take home points:

  • All patients with COVID-19 should be considered to be at high risk of VTE (SR, MQE).
  • Standard prophylactic dose of unfractionated or low molecular weight heparin is recommended for all hospitalized patients (SR, HQE).
  • Extended prophylaxis should be considered after hospital discharge (45 days) (SR, WQE).
  • Suspected pulmonary thromboembolism (PTE) should be treated as PTE (SR, VLQE).

Convalescent Plasma Therapy

Plasma from donors who have recovered from COVID-19 may contain antibodies, which could have antiviral and anti-inflammatory properties. This was demonstrated to be feasible and safe.30 The first RCT on convalescent plasma therapy (CPT) for COVID-1931 was terminated early due to the clearance of the pandemic in China. Just over 100 patients completed the study. Negative PCR results on repeat testing were reported in a higher number of patients treated with convalescent plasma.32,33 Disease severity and 28-day survival, however, did not differ.

Indian Society of Critical Care Medicine Position—New take home point:

  • There are insufficient data either to recommend in favor or against CPT for COVID-19 (SR, LQE).

There are insufficient data either to recommend in favor or against CPT for COVID-19. However, units planning to use CPT are advised to follow stringent donor and recipient selection criteria.

Donor Selection

Evidence of COVID-19 documented by a laboratory test either by a diagnostic test (e.g., nasopharyngeal swab) at the time of illness or

A positive serological test for SARS-CoV-2 antibodies after recovery.

Complete resolution of symptoms at least 14 days prior to donation.

Male donors, or female donors who have not been pregnant, or female donors who have been tested since their most recent pregnancy and results interpreted as negative for HLA antibodies.

When measurement of neutralizing antibody titers is available, neutralizing antibody titers of at least 1:160 is recommended.

A titer of 1:80 may be considered acceptable if an alternative matched unit is not available.

Recipient Criteria

Laboratory confirmed COVID-19:

  • Severe or immediately life-threatening COVID-19.Severe disease is defined as one or more of the following:
  • Dyspnea.
  • Tachypnea ≥30/minute.
  • Blood oxygen saturation ≤93%.
  • PaO2/FiO2 <300.
  • Lung infiltrates %3E;50% within 24–48 hours.

The life-threatening disease is defined as one or more of the following:

  • Respiratory failure.
  • Septic shock.
  • Multiple organ dysfunction.

Cytokine Storm

The cytokine storm is an acute hyperinflammatory response that has been implicated in severe forms of COVID-19. Mehta et al.34 have described the syndrome in detail. They have drawn an analogy with secondary hemophagocytic lymphohistiocytosis. Corticosteroids, heparin, convalescent plasma, IL-6 inhibitors, and extracorporeal removal have been proposed as possible therapeutic strategies against cytokine storm.

Indian Society of Critical Care Medicine Position—New take home points:

  • The cytokine storm has a definite clinical and biochemical pattern (SR, HQE).
  • Multiple strategies may be used in combination to manage this complication (SR, HQE).

Cardiopulmonary Resuscitation during COVID-19

The American Heart Association (AHA) issued interim guidelines for CPR during the pandemic. The guideline acknowledged the increased risk of exposure to healthcare workers and the fact that performing CPR involves numerous aerosol-generating procedures. CPR also involves numerous professionals working in close proximity. The guideline emphasized on PPE use, limiting the number of personnel involved, and using mechanical devices for CPR where possible. Contrary to usual recommendation, the AHA recommends pausing chest compressions for intubation.

Indian Society of Critical Care Medicine Position:

  • CPR should be initiated as per clinical requirement (SR, LQE).
  • All rescuers should don full PPE (SR, HQE).
  • Number of personnel should be limited (BPS).
  • Guidelines issued by the AHA need to be understood and all code blue teams should have reorientation regarding the same (SR, LQE).
  • CPR may be tried in prone position if patient is already prone, if already intubated, guided by invasive arterial blood pressure monitoring and or ETCO2 monitoring (SR, VLQE).
  • Defibrillation in prone patients can be done with pads positioned anterior-posteriorly, or in bi-axillary regions (SR, LQE).

Discharge Criteria

The WHO has updated the criteria for discharge of the patients from isolation.29,35 The WHO mentions that this guidance applies to all categories of patients irrespective of disease severity and location of treatment. The updated de-isolation guidelines are based on the symptom-free interval. The Ministry of Health and Family Welfare (MOHFW) has also made similar recommendations32,36 for discharge of patients with moderate COVID-19. For severe cases, the MOHFW recommends discharge only after symptom resolution and one negative PCR rest.

Indian Society of Critical Care Medicine Position—Updated take home points:

  • Negative PCR is no longer mandatory for discharge of moderately sick patients from isolation.
  • For mild to moderately symptomatic patients, a 3-day symptom-free period following a 10-day isolation after symptom onset is enough for de-isolation.
  • For asymptomatic patients, 10 days after a positive test is enough for de-isolation.
  • For severely symptomatic patients, one negative PCR test is enough to consider discharge from isolation.

REFERENCES

1. Frat JP, Thille AW, Mercat A, Girault C, Ragot S, Perbet S, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med 2015;372(23):2185–2196. DOI: 10.1056/NEJMoa1503326.

2. Paul V, Patel S, Royse M, Odish M, Malhotra A, Koenig S. Proning in non-intubated (PINI) in times of COVID-19: case series and a review. J Intensive Care Med 2020;35(8):818–824. DOI: 10.1177/0885066620934801.

3. Koeckerling D, Barker J, Mudalige NL, Oyefeso O, Pan D, Pareek M, et al. Awake prone positioning in COVID-19. Thorax 2020;75(10):833–834. DOI: 10.1136/thoraxjnl-2020-215133.

4. Haiduc AA, Alom S, Melamed N, Harky A. Role of extracorporeal membrane oxygenation in COVID-19: a systematic review. J Card Surg 2020. 1–9. DOI: 10.1111/jocs.14879.

5. Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med 2020;8(6):46. DOI: 10.1016/S2213-2600(20)30216-2.

6. Shekar K, Badulak J, Peek G, Boeken U, Dalton HJ, Arora L, et al. Extracorporeal life support organization coronavirus disease 2019 interim guidelines: a consensus document from an international group of interdisciplinary extracorporeal membrane oxygenation providers. ASAIO J 2020;66(7):707–721. DOI: 10.1097/MAT.0000000000001193.

7. Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA 2020;324(13):1–11. DOI: 10.1001/jama.2020.17021.

8. Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, Beane A, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA 2020;324(13):1317–1329. DOI: 10.1001/jama.2020.17022.

9. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of COVID-19—preliminary report. N Engl J Med 2020. DOI: 10.1056/NEJMoa2007764 Available at: https://pubmed.ncbi.nlm.nih.gov/32445440.

10. Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med 2020;383(6):517–525. DOI: 10.1056/NEJMoa2016638.

11. Furtado RHM, Berwanger O, Fonseca HA, Corrêa TD, Ferraz LR, Lapa MG, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet 2020(10256). DOI: 10.1016/S0140-6736(20)31862-6.

12. Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state. JAMA 2020;323(24):2493–2502. DOI: 10.1001/jama.2020.8630.

13. Jeronimo CMP, Farias MEL, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, et al. Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial. Clin Infect Dis 2020. ciaa1177. DOI: 10.1093/cid/ciaa1177.

14. Horby P, Lim WS, Mafham M, Bell JL, Linsell L, Staplin N, et al. Dexamethasone in hospitalized patients with COVID-19—preliminary report. N Engl J Med. 2020. NEJMoa2021436 Available at: https://www.ncbi.nlm.nih.gov/pubmed/32678530.

15. Chowdhury ATMM, Shahbaz M, Karim M, Islam J, Guo D, Shuixiang. H. A comparative study on ivermectin-doxycycline and hydroxychloroquine-azithromycin therapy on COVID19 patients. 2020. DOI: 10.13140/RG.2.2.22193.81767/3.

16. Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses–drug discovery and therapeutic options. Nat Rev Drug Discov 2016;15(5):327–347. DOI: 10.1038/nrd.2015.37 Available at: https://www.ncbi.nlm.nih.gov/pubmed/26868298.

17. Tahir ul Qamar M, Alqahtani SM, Alamri MA, Chen L. Structural basis of SARS-CoV-2 3CLpro and anti- COVID-19 drug discovery from medicinal plants. J Pharm Anal 2020(4). DOI: 10.1016/j.jpha.2020.03.009 Published online ahead of print. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156227/.

18. Liu X, Wang XJ. Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines. J Genet Genomics 2020;47(2):119–121. DOI: 10.1016/j.jgg.2020.02.001 Available at: https://www.ncbi.nlm.nih.gov/pubmed/32173287.

19. Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, et al. Association between administration of systemic corticosteroids and mortality among critically Ill patients with COVID-19: a meta-analysis. JAMA 2020;324(13):1–13. DOI: 10.1001/jama.2020.17023.

20. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–1578. Available at: https://pubmed.ncbi.nlm.nih.gov/32423584.

21. Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, et al. Remdesivir for 5 or 10 days in patients with severe COVID-19. N Engl J Med 2020. DOI: 10.1056/NEJMoa2015301NEJMoa2015301 . Available at https://www.ncbi.nlm.nih.gov/pubmed/32459919.

22. Jiang Y, Chen D, Cai D, Yi Y, Jiang S. Effectiveness of remdesivir for the treatment of hospitalized Covid-19 persons: a network meta-analysis. J Med Virol 2020. DOI: 10.1002/jmv.26443.

23. Spinner CD, Gottlieb RL, Criner GJ, Arribas López JR, Cattelan AM, Soriano Viladomiu A, et al. GS-US-540-5774 Investigators. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA 2020;324(11):1048–1057. DOI: 10.1001/jama.2020.16349.

24. Roche. Roche provides an update on the Phase III COVACTA trial of Actemra/RoActemra in hospitalized patients with severe COVID-19 associated pneumonia. 2020. Available at: https://www.roche.com/investors/updates/inv-update-2020-07-29.htm.

25. Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmun Rev 2020;19(7):102568. DOI: 10.1016/j.autrev.2020.102568.

26. Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, Wang L, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. medRxiv [Preprint] 2020. DOI: 10.1101/2020.05.29.20117358Update in: Clin Infect Dis. 2020 Jul 11.

27. Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. High risk of thrombosis in patients in severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 2020(6). DOI: 10.1007/s00134-020-06062-x[Preprint] . Available at: https://www.esicm.org/wp-content/uploads/2020/04/863_author_proof.pdf.

28. Synairgen announces positive results from trial of SNG001 in hospitalised COVID-19 patients [press release]. July 20, 2020. Available at: https://www.synairgen.com/wp-content/uploads/2020/07/200720-Synairgenannounces-positive-results-from-trial-of-SNG001-in-hospitalised-COVID-19-patients.pdf .Accessed August 24, 2020.

29. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance 28 January 2020. 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019?gclid=CjwKCAjwltH3BRB6EiwAhj0IUJRqLu9rsxDNY77_ZNY7Qjope43aZzx4TrNXKftBB0RMwXAa45KFgBoCYh4QAvD_BwE.

30. Davoudi-Monfared E, Rahmani H, Khalili H, Hajiabdolbaghi M, Salehi M, Abbasian L, et al. A randomized clinical trial of the efficacy and safety of interferon beta-1a in treatment of severe COVID-19. Antimicrob Agents Chemother 2020;64(9):e01061-20. DOI: 10.1128/AAC.01061-20 Available at: https://www.ncbi.nlm.nih.gov/pubmed/32661006.

31. Llitjos JF, Leclerc M, Chochois C, Monsallier J-M, Ramakers M, Auvray M, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost 2020(7). DOI: 10.1111/jth.14869 Available at: https://www.ncbi.nlm.nih.gov/pubmed/32320517.

32. Joyner MJ, Bruno KA, Klassen SA, Kunze KL, Johnson PW, Lesser ER, et al. Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients. Mayo Clin Proc 2020;95(9):1888–1897. DOI: 10.1016/j.mayocp.2020.06.028 Available at: https://mayoclinicproceedings.org/pb/assets/raw/Health%20Advance/journals/jmcp/jmcp_ft95_6_8.pdf.

33. Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of convalescent plasma therapy on time to clinical improvement in Patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 2020;324(5):460–470. DOI: 10.1001/jama.2020.10044Erratum in. JAMA 2020;324(5):519.

34. Mehta Y, Dixit SB, Zirpe KG, Ansari AS. Cytokine storm in novel coronavirus disease (COVID-19): expert management considerations. Indian J Crit Care Med 2020;24(6):429–434. DOI: 10.5005/jp-journals-10071-23415.

35. World Health Organization, Clinical management of COVID-19 (Interim Guidance) https://www.who.int/publications-detail/clinical-management-of-covid-19,published 27 May 2020.

36. https://www.mohfw.gov.in/pdf/FinalGuidanceonMangaementofCovidcasesversion2.pdf).